^
    2ms
    Pembrolizumab with Intratumoral Injection of Clostridium Novyi-NT (clinicaltrials.gov)
    P1, N=18, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Oct 2024 --> Oct 2026 | Trial primary completion date: Oct 2024 --> Oct 2026
    Trial completion date • Trial primary completion date • Combination therapy
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • Clostridium novyi-NT
    8ms
    Pembrolizumab With Intratumoral Injection of Clostridium Novyi-NT (clinicaltrials.gov)
    P1, N=18, Active, not recruiting, M.D. Anderson Cancer Center | Recruiting --> Active, not recruiting
    Enrollment closed • Combination therapy
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • Clostridium novyi-NT
    over2years
    Pembrolizumab With Intratumoral Injection of Clostridium Novyi-NT (clinicaltrials.gov)
    P1, N=18, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Oct 2021 --> Oct 2024 | Trial primary completion date: Oct 2021 --> Oct 2024
    Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • Clostridium novyi-NT
    5years
    Pembrolizumab With Intratumoral Injection of Clostridium Novyi-NT (clinicaltrials.gov)
    P1, N=18, Recruiting, M.D. Anderson Cancer Center | Trial primary completion date: Oct 2020 --> Oct 2021
    Clinical • Trial primary completion date • Combination therapy
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • Clostridium novyi-NT